SARS-CoV-2 Research Antibodies

SARS-CoV-2 is a virus that causes the acute respiratory syndrome, COVID-19. Research has shown that the virus enters cells by interacting with the host ACE-2 receptor through the SARS-CoV-2 Spike protein Receptor-Binding Domian (RBD). Vaccine and drug discovery has revolved around understanding the interaction between the Spike protein and ACE2 while immunoassay test development has primarily focused on the Nucleocapsid (NP) protein of SARS-CoV-2. To support COVID-19 RnD scientists, Assay genie have developed a range of antibodies including tagged and untagged polyclonal, monoclonal & recombinant antibodies to nanobodies and neutralizing antibodies.

Key Features

  • Activity Tested: Comprehensive activity data for neutralizing antiboduies
  • Comprehensive Choice: Choose from polyclonal & monoclonal antibodies as well as Nanobodies
  • Technologically Advanced: Recombinant and tagged antibodies inlcuded in the range
  • Flexible: Tested in multiple applications including ELISA, IF, WB and activity assays

SARS-CoV-2 Spike Protein Antibodies

Product Code Product Name Conjugatation Application
AGEL2109 SARS-CoV-2 Spike Protein Monoclonal Antibody [5D9] Unconjugated ELISA
AGEL2110 SARS-CoV-2 Spike Protein Monoclonal Antibody [D001] Unconjugated WB, ELISA
AGEL2111 SARS-CoV-2 Spike Protein Monoclonal Antibody [D003] Unconjugated WB, ELISA
AGEL2112 SARS-CoV-2 Spike S1 Monoclonal Antibody [R007] Unconjugated IF, ELISA
PACOV0001 SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] Unconjugated ELISA, GICA
PACOV0004 SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] HRP-conjugated HRP ELISA
PACOV0005 SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] FITC-conjugated FITC ELISA
PACOV0006 SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] Biotin-conjugated Biotin ELISA
CAB20017 SARS-COV-2 Spike Protein Polyclonal Antibody Unconjugated IHC, IF, IP, FC, ELISA
CPAB0418 SARS-CoV-2 IgG Spike S1 Recombinant Monoclonal Antibody Unconjugated ELISA
CPAB0419 SARS-CoV-2 IgM Kappa Spike S1 Recombinant Monoclonal Antibody Unconjugated ELISA

SARS-CoV-2 Spike RBD Antibodies

Product Code Product Name Conjugatation Application
AGEL2113 SARS-CoV-2 Spike Protein RBD Polyclonal Antibody Unconjugated WB, ELISA
PACOV0003 SARS-CoV-2 Spike Protein RBD Nanobody [A1] Unconjugated ELISA, GICA, Neutralising

SARS-CoV-2 Spike Neutralizing Antibodies

Product Code Product Name Conjugatation Application
PACOV0002 SARS-CoV-2 Spike Protein Neutralizing Monoclonal Antibody [H6] Unconjugated ELISA, GICA, Neutralising
AGEL2120 SARS-CoV-2 Spike-hIgG1 Neutralizing Antibody Unconjugated Neutralization, ELISA
AGEL2121 SARS-CoV-2 Spike-mIgG1 Neutralizing Antibody Unconjugated Neutralization, ELISA
AGEL2122 SARS-CoV-2 S-cIgG1 Neutralizing Antibody Unconjugated Neutralization, ELISA
AGEL2123 SARS-CoV-2 Spike Neutralizing Antibody Unconjugated Neutralization, ELISA
AGEL2124 SARS-CoV-2 Spike Neutralizing Antibody (RBD, mFc Tag) Unconjugated Neutralization, ELISA

SARS-CoV-2 Nucleocapsid Antibodies

Product Code Product Name Conjugatation Application
AGEL2114 SARS-CoV-2 Nucleocapsid Monoclonal Antibody [6G9] Unconjugated ELISA
AGEL2116 SARS-CoV-2 Nucleocapsid Monoclonal Antibody [M05] Unconjugated WB, ELISA
AGEL2117 SARS-CoV-2 Nucleocapsid Monoclonal Antibody [R001] Unconjugated WB, ELISA
PACOV0007 SARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] Unconjugated ELISA, GICA
PACOV0008 SARS-CoV-2 Nucleocapsid Monoclonal Antibody (WB) [1A6] Unconjugated ELISA, WB, GICA
PACOV0009 SARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] HRP-conjugated HRP ELISA
PACOV0010 ARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] FITC-conjugated FITC ELISA
PACOV0011 SARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] Biotin-conjugated Biotin ELISA
CAB20016 SARS-COV-2 Nucleocapsid Polyclonal Antibody Unconjugated WB, IHC, IF, IP, FC, ELISA

Anti-ACE2 Antibodies | Human, Mouse & Rat

Product Code Product Name Conjugatation Application
AGEL2118 ACE2 Polyclonal Antibody (Human, Mouse, Rat) Unconjugated IHC, ELISA
CAB4612 ACE2 Rabbit Monoclonal Antibody (Human, Mouse, Rat) Unconjugated WB, IHC
CAB12737 ACE2 Polyclonal Antibody (Human, Mouse, Rat) Unconjugated WB, IHC, IF

Anti-ACE2 Antibodies | Human

Product Code Product Name Conjugatation Application
PACO47046 ACE2 Polyclonal Antibody Unconjugated IHC, IF, ELISA
PACO47047 ACE2 Antibody, HRP-conjugated HRP ELISA
PACO47048 ACE2 Antibody, FITC-conjugated FITC ELISA
PACO47049 ACE2 Antibody, Biotin-conjugated Biotin ELISA

Anti-ACE2 Antibodies | Rat

Product Code Product Name Conjugatation Application
PACO64123 ACE2 Polyclonal Antibody Unconjugated WB, ELISA
PACO64124 ACE2 Antibody, HRP-conjugated HRP ELISA
PACO64125 ACE2 Antibody, FITC-conjugated FITC ELISA
PACO64126 ACE2 Antibody, Biotin-conjugated Biotin ELISA

SARS-CoV-2 Information

In-depth research is required to understand and uncover the innate and adaptive immune responses elicited by COVID-19 infection and the immunological and cardiovascular pathways that likely contribute to disease severity. This research will contribute to theĀ  development of a vaccine versus the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and the development of therapeutics and anti-virals to prevent and/or repress SARS-CoV-2 infection. To support COVID-19 research we have developed some key biological research tools including SARS-CoV-2 & ACE 2 Antibodies.

SARS-CoV-2 Spike protein and ACE2 interaction

SARS-CoV-2, the causative viral agent of the disease COVID-19, is a coronavirus which bears the transmembrane glycoprotein spikes (S protein) typical of viruses in its clade. These spikes are a prominent target of human immune responses and have been found to be highly immunogenic. The receptor-binding domain (RBD) of the S protein is particularly targeted by neutralising antibodies.

The spike protein is a heavily-glycosylated, cell-surface protein which mediates viral entry into host cells. The spikes on SARS-CoV-2 allows the virus to enter host cells through the human receptor angiotensin converting enzyme 2 (ACE2), present in alveolar epithelial cells. ACE2, a carboxypeptidase, is part of the renin-angiotensin system (RAS), and has been shown to be a functional receptor of the human coronaviruses SARS-CoV and SARS-CoV-2.The S protein RBD and ACE2 interaction is explained in great detail in this article.

Spike protein is necessary for attachment to susceptible cells. The spike protein is composed of both an S1 domain and S2 domain. S1 contains a receptor-binding domain. The receptor-binding domain of the spike protein mediates an interaction with angiotensin-converting enzyme 2 (ACE2). Neutralising antibody responses, mainly to the Spike protein, begin to develop by week 2 of infection onset and most patients develop neutralising antibodies by week 3.

SARS-CoV-2 Nucleocapsid (N) protein

The time between initial viral exposure and symptom onset is known as the incubation period. For COVID-19, the average incubation period has been reported to be between five and six days, however, there is considerable variation in incubation time.

In patients with SARS-CoV infection, B cell responses are activated firstly against the nucleocapsid (N) protein of SARS-CoV-2. The N protein is one of the most abundant structural proteins during SARS-CoV-2 infection. The role of the N protein is to package the positive strand viral genome RNA into a helical ribonucleocapsid (RNP). The SARS-CoV-2 N protein also plays a role during virion assembly through its interactions with the viral genome and membrane protein M.

Within 4–8 days after symptoms present, antibody responses against the spike (S) protein of the virus are found. Neutralising antibody responses, mainly to the S protein, begin to develop by week 2 of infection onset and most patients develop neutralising antibodies by week 3.

SARS-CoV-2 & ACE 2 Antibodies

To support the efforts of researchers across the globe, ELISA Genie has developed SARS-CoV-2 receptor ACE2 antibodies, spike protein antibodies, nucleoprotein antibodies and more. These antibody research tools will contribute to understanding and combating COVID-19 virus SARS-COV-2 and other coronaviruses.